|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians显示文摘Pancreatic cancer(PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease. | Rosella Spadi Federica Brusa Agostino Ponzetti Isabella Chiappino Nadia Birocco Libero Ciuffreda Maria Antonietta Satolli | 2016 | World Journal of Clinical Oncology2016，7，1： | 15 |
| 2 | Extracorporeal CO2 re- moval显示文摘 | Terragni PP Birocco A Faggiano C | 2010 | ContribNephrol2010，165，： | 1 |
| 3 | Tidal volume lower than 6 ml/kg enhances lung protec- tion: role of extracorporeal carbon dioxide removal显示文摘 | Terragni PP Del SL Mascia L Urbino R Martin EL Birocco A | 2009 | Anesthesi- ology2009，111，4： | 1 |
| 4 | ECMO criteria for influenza A ( H1 N1 ) -associated ARDS : role of transpulmonary pressure 显示文摘 | Grasso S Terragni P Birocco A | 2012 | Intensive Care Med2012，38，： | 1 |
| 5 | ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure 显示文摘 | Grasso S Terragni P Birocco A | 2012 | Intensive Care Med2012，38，3： | 1 |
| 6 | Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma:a phase Ⅱ study显示文摘 | Schena M Barone C Birocco N | 2005 | Cancer Chemother Pharmacol2005，55，3： | 1 |
| 7 | Tidal Volume Lower than 6 ml/kg Enhances Lung Protection: Role of Extracorporeal Carbon Dioxide Removal显示文摘 | Pier Paolo Terragni Lorenzo Del Sorbo Luciana Mascia Rosario Urbino Erica L. Martin Alberto Birocco Chiara Faggiano Michael Quintel Luciano Gattinoni V Marco Ranieri | 2009 | Anesthesiology2009，，： | 1 |
| 8 | ECMO criteria for influenza A ( H1 N1 ) -associated ARDS : role of transpulmonary pressure显示文摘 | Grasso S Terragni P Birocco A | 2012 | Intensive Care Med2012，38，3： | 1 |
| 9 | Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues显示文摘 | Marco Volante Nadia Birocco Gaia Gatti Eleonora Duregon Katia Lorizzo Nicola Fazio Giorgio V. Scagliotti Mauro Papotti | 2014 | Human Pathology2014，，： | 1 |
| 10 | ECMO criteria for influenza A ( H1 N1 ) - associated ARDS : role of transpulmonary pressure显示文摘 | Grasso S Terragni P Birocco A | 2012 | In- tensive Care Med2012，38，7： | 1 |
| 11 | Weekly cisplatin pa- clitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study显示文摘 | Schena M Barone C Birocco N | 2005 | Cancer ChemotherPharmacol2005，55，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员